House Bill 177 amends Section 26-3-3 NMSA 1978, which is entitled “Drug Product Selection Permitted – Conditions – Exception for Prohibition—Labelling,” with the effect that pharmacists would have wider authority to substitute therapeutically equivalent drugs for drugs that have been prescribed by a medical care provider than is currently granted. HB177 would allow pharmacists to substitute a drug in the same therapeutic class that the pharmacist felt would have a substantially similar effect even if the drug is not a therapeutically equivalent drug.